Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tranexamic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG known ✓ | P00747 | 1/20 | 1.00 |
| ▸ | PLAT | P00750 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ANPEP | P15144 | 1/20 | 0.52 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.42 |
| ▸ | GABRE | P78334 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tranexamic Acid SCHEMBL16974 | 1.00 | PLG (1.00) | PLGPLATLMNAANPEPENPEP | |
| Tranexamic Acid SCHEMBL186034 | 1.00 | PLG (1.00) | PLGPLATLMNAANPEPENPEP | |
| Tranexamic Acid SCHEMBL349408 | 1.00 | PLG (1.00) | PLGPLATLMNAANPEPENPEP | |
| Tranexamic Acid SCHEMBL322487 | 1.00 | PLG (1.00) | PLGPLATLMNAANPEPENPEP | |
| Tranexamic Acid SCHEMBL19031783 | 0.98 | PLG (0.95) | PLGPLATLMNAANPEPENPEP | |
| Tranexamic Acid SCHEMBL3793503 | 0.98 | PLG (0.95) | PLGPLATLMNAANPEPENPEP | |
| Tranexamic Acid SCHEMBL11189660 | 0.98 | PLG (0.95) | PLGPLATLMNAANPEPENPEP | |
| Tranexamic Acid SCHEMBL10723480 | 0.98 | PLG (0.95) | PLGPLATLMNAANPEPENPEP | |
| Tranexamic Acid SCHEMBL7326280 | 0.98 | PLG (0.95) | PLGPLATLMNAANPEPENPEP | |
| Tranexamic Acid SCHEMBL29236634 | 0.98 | PLG (0.95) | PLGPLATLMNAANPEPENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019168654-A9 | DNA-TEMPLATED MACROCYCLE LIBRARY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-10-17 | — | — | WO | disclosed |
| US-20120022160-A1 | COMPOSITION FOR EXTERNAL USE ON SKIN | SHISEIDO COMPANY LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-7989641-B2 | Methods of synthesizing N-hydroxysuccinimidyl carbonates | XENOPORT, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110184060-A1 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A TRANEXAMIC ACID PRODRUG | XENOPORT, INC. | 2011-07-28 | — | — | US | disclosed |
| WO-2011078903-A1 | COSMETIC COMPOSITIONS COMPRISING FIBROUS PIGMENTS | AVON PRODUCTS, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110150947-A1 | Cosmetic Compositions Comprising Fibrous Pigments | AVON PRODUCTS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110009483-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-5472851-A | Converting plasminogen to plasmin and the assaying plasmin resulting from said conversion; inhibiting plsma proteins alpha2-antiplsmin and alpha2-macroglobulin by contact with metalloproteinase | SERBIO (FR) | 1995-12-05 | — | — | US | disclosed |
| US-4689346-A | Therapeutic 1-(acylamino)-naphthalene-4-sulphonic acid derivatives | LABORATORIO FIDES, S.A. (ES) | 1987-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009483-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | ACMSD, APEH, CPS1 | PLG 19/4885PLAT 17/4885LMNA 946/4885 |
| US-20110184060-A1 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A TRANEXAMIC ACID PRODRUG | F2, PROC, PLAT | PLG 9/4885PLAT 3/4885LMNA 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.